Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review...

Descripción completa

Detalles Bibliográficos
Autores principales: Owji, Shayan, Caldas, Stella A, Ungar, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/
https://www.ncbi.nlm.nih.gov/pubmed/36316998
http://dx.doi.org/10.2147/JAA.S342051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/
https://www.ncbi.nlm.nih.gov/pubmed/36316998
http://dx.doi.org/10.2147/JAA.S342051

Ejemplares similares